The company has issued more shares over this period, which dilutes each existing shareholder’s stake.
Diluted shares outstanding: 20.2M (2019) → 27.5M (2024)
Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.
When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.
Revenue data limited
-162.5% YoY
YoY Growth Rate
Earnings declining
$26,000/ year
↓ Declining (-100% vs prior year)
R&D spend declining — could signal cost-cutting or efficiency
~7 months
$867,000 cash & investments
Short runway — potential dilution ahead through share issuance
Ocean Biomedical has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.
The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.
Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
